Deals this week: eFFECTOR Therapeutics, VenatoRx Pharmaceuticals, Kezar Life Sciences
US-based biotech company eFFECTOR Therapeutics has secured $38.6m in a series C venture financing round led by Pfizer Venture Investments (PVI). (Source: Drug Development Technology)
Source: Drug Development Technology - July 27, 2017 Category: Pharmaceuticals Source Type: news
M & As this week: BriaCell Therapeutics, Lentigen Technology
BriaCell Therapeutics plans to acquire Sapientia Pharmaceuticals through its subsidiary BriaCell Therapeutics (BriaCell USA). (Source: Drug Development Technology)
Source: Drug Development Technology - July 27, 2017 Category: Pharmaceuticals Source Type: news
Verona Pharma begins RPL554 dosing in Phase IIb trial for COPD
UK-based biopharmaceutical firm Verona Pharma has begun dosing patients in a Phase IIb clinical trial of RPL554 as a maintenance treatment for patients with chronic obstructive pulmonary disease (COPD). (Source: Drug Development Technology)
Source: Drug Development Technology - July 26, 2017 Category: Pharmaceuticals Source Type: news
Retrophin doses first patient in Phase III trial of RE-024 for PKAN
Retrophin has started dosing patients in a Phase III Fosmetpantotenate Replacement Therapy (FORT) clinical trial of RE-024 to treat patients with pantothenate kinase-associated neurodegeneration (PKAN). (Source: Drug Development Technology)
Source: Drug Development Technology - July 26, 2017 Category: Pharmaceuticals Source Type: news
Neon Therapeutics and Apexigen start Phase IIb combination trial for melanoma
Immuno-oncology firm Neon Therapeutics has partnered with biopharmaceutical company Apexigen to investigate its NEO-PV-01 in combination with APX005M in a Phase IIb trial to treat patients with metastatic melanoma. (Source: Drug Development Technology)
Source: Drug Development Technology - July 26, 2017 Category: Pharmaceuticals Source Type: news
Tremfya (guselkumab) for the Treatment of Plaque Psoriasis
Tremfya ™ (guselkumab) is a biologic approved for the treatment of adults living with moderate to severe plaque psoriasis. (Source: Drug Development Technology)
Source: Drug Development Technology - July 25, 2017 Category: Pharmaceuticals Source Type: news
BlackThorn starts enrolment in Phase IIa trial for MDD drug
US-based biopharmaceutical firm BlackThorn Therapeutics has started patient enrolment in a Phase IIa clinical trial of BTRX-246040 to treat adults with major depressive disorder (MDD). (Source: Drug Development Technology)
Source: Drug Development Technology - July 25, 2017 Category: Pharmaceuticals Source Type: news
Janssen reports positive results from Phase III darunavir-based HIV regimen trial
Janssen-Cilag International has reported positive results from a Phase III clinical trial (EMERALD) of darunavir containing a single-tablet regimen (STR) in patients with human immunodeficiency virus type 1 (HIV-1). (Source: Drug Development Technology)
Source: Drug Development Technology - July 25, 2017 Category: Pharmaceuticals Source Type: news
NCI and COG initiate paediatric Phase II trial for precision cancer drugs
The National Institutes of Health ’s (NIH) unit National Cancer Institute (NCI) and the Children’s Oncology Group (COG) have initiated patient enrolment in a paediatric Phase II clinical trial to evaluate targeted cancer medicines. (Source: Drug Development Technology)
Source: Drug Development Technology - July 25, 2017 Category: Pharmaceuticals Source Type: news
Customised Crystallisation and Filtration System
Systag's crystallisation and filtration system helps increase your flexibility, productivity, and optimises your documentation. (Source: Drug Development Technology)
Source: Drug Development Technology - July 25, 2017 Category: Pharmaceuticals Source Type: news
Bayer ’s Phase II trial for MPM drug fails to meet primary endpoint
Bayer ’s Phase II clinical trial of its oncology product candidate anetumab ravtansine (BAY 949343) did not meet the primary endpoint of progression-free survival in recurrent malignant pleural mesothelioma (MPM) patients. (Source: Drug Development Technology)
Source: Drug Development Technology - July 24, 2017 Category: Pharmaceuticals Source Type: news
Biohaven begins enrolment in Phase III trial of rimegepant for migraine
Biohaven Pharmaceutical Holding has begun patient enrolment in the first of two Phase III clinical trials planned for its product candidate rimegepant (BHV-3000) for acute treatment of migraine. (Source: Drug Development Technology)
Source: Drug Development Technology - July 24, 2017 Category: Pharmaceuticals Source Type: news
Stealth BioTherapeutics studies elamipretide in Phase II/III trial for Barth syndrome
US-based Stealth BioTherapeutics has started a Phase II/III TAZPOWER clinical trial to investigate its product candidate elamipretide to treat patients with Barth syndrome caused due to TAZ gene mutations. (Source: Drug Development Technology)
Source: Drug Development Technology - July 24, 2017 Category: Pharmaceuticals Source Type: news
SillaJen and Lee's Pharma to initiate Phase III liver cancer trial of Pexa-Vec
South Korean biotherapeutics firm SillaJen and Hong Kong-based biopharmaceutical company Lee's Pharmaceutical Holdings have secured approval from the China Food and Drug Administration (CFDA) for a Phase III clinical trial (PHOCUS) of Pexa-Vec in pat … (Source: Drug Development Technology)
Source: Drug Development Technology - July 23, 2017 Category: Pharmaceuticals Source Type: news
Endari for the Treatment of Sickle Cell Disease
Endari ™ is an orally-administered powder form of amino acid L-glutamine indicated for the treatment of sickle cell disease. (Source: Drug Development Technology)
Source: Drug Development Technology - July 23, 2017 Category: Pharmaceuticals Source Type: news
